Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

120
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
120
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

388
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
388
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
144
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

335
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
335

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Call to Investigate the Association Between Histoplasmosis and Fatigue.

Open forum infectious diseases·2026
Same author

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions.

Journal of fungi (Basel, Switzerland)·2026
Same author

Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials.

Open forum infectious diseases·2026
Same author

The New Path Forward for Prior Authorizations: Navigating Differences in the Accepted Standards of Care, Society Guidelines, and FDA-approved Indications.

Open forum infectious diseases·2026
Same author

Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database.

Open forum infectious diseases·2025
Same author

Comparative Outcomes Following <i>Candida</i> Bloodstream Infection in Patients With Left Ventricular Assist Devices.

Open forum infectious diseases·2025

相关实验视频

Updated: Jun 5, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.6K

与伊特拉可纳治疗相关的副作用

Matthew R Osborn1, Julio C Zuniga-Moya1, Patrick B Mazi1

  • 1Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, 4523 Clayton Ave, MSC 8051-0043-15, St. Louis, MO 63110, USA.

The Journal of antimicrobial chemotherapy
|December 10, 2024
PubMed
概括

长期治疗伊特拉科纳治疗细胞质粒异位症,导致大约四分之一的患者出现副作用. 较高的伊特拉科纳血清水平与不良事件有关,这表明监测可能会改善治疗结果.

科学领域:

  • 医学真菌学 医学真菌学
  • 临床药理学 临床药理学

背景情况:

  • 伊特拉可纳是治疗菌感染的首要治疗方法,如组织等离子体感染.
  • 与短期使用相比,关于伊特拉可纳的长期副作用的数据有限.
  • 可纳通常被认为更安全,在长期治疗环境中表现出显著的毒性.

研究的目的:

  • 评估伊特拉科纳在组织等离子体病患者的副作用的频率,性质和时间.
  • 分析因副作用而导致的治疗修改.
  • 调查患者特征,伊特拉可纳血清水平和副作用发生之间的关系.

主要方法:

  • 一个回顾性,单中心的研究,成年基因质等离子体病患者接受伊特拉科纳治疗≥28天 (2002-2021年).
  • 报告的副作用的表征.
  • 倾向性得分匹配,以比较具有和没有副作用的患者的伊特拉科纳血清水平.

主要成果:

  • 27.8%的患者 (63/227) 经历了至少一种副作用.
  • 常见的副作用包括肝毒性 (7.0%),恶心/吐 (6.6%) 和腹 (6.2%).
  • 有副作用的患者 (P=0.009) 观察到更高的中位数伊特拉可纳血清水平 (2.9vs1.8mcg/mL).

更多相关视频

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

相关实验视频

Last Updated: Jun 5, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.6K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

结论:

  • 大约25%的患者长期服用伊特拉科纳治疗血清发生病报告了副作用.
  • 近三分之二的受影响患者需要治疗干预,包括减少剂量或停止治疗.
  • 与其他研究中弗卢科纳相比,伊特拉科纳的副作用频率较低.